Literature DB >> 20855185

Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale.

R Andrew Sewell1, Edward B Perry, Laurence P Karper, Morris D Bell, Paul Lysaker, Joseph L Goulet, Louise Brenner, Joseph Erdos, D Cyril d'Souza, John P Seibyl, John H Krystal.   

Abstract

BACKGROUND: Nonlocalizing neurologic deficits detectable by clinical evaluation-"soft signs"-are a robust finding in patients diagnosed with schizophrenia, but their conceptual and neuroanatomical correlates remain unclear. The purpose of this study was to evaluate the organization of these deficits and their clinical correlates using the Neurological Evaluation Scale (NES).
METHODS: Ninety-three male veterans with schizophrenia and schizoaffective disorder were evaluated using a detailed clinical assessment that included the NES, the Extrapyramidal Symptom Rating Scale, the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Scale, the Positive and Negative Syndrome Scale, the Wisconsin Card Sorting Test (WCST), the Schedule for the Deficit Syndrome (SDS), and the Digit Symbol Substitution Task (DSST).
RESULTS: Four factors explained 73% of the variance and had distinct clinical and neuropsychological correlates. Factor 1 reflected deficits involved with memory and sensory integration, and was associated with lower PANSS positive and higher AIMS scores. Factor 2 reflected impairments in motor control, and was associated with lower intelligence, more cognitive deficits, and deficit-syndrome schizophrenia. Factor 3 was related to lower intelligence and more perseverative errors on the WCST. Factor 4 was related to increasing age, more extrapyramidal symptoms, more perseverative errors, and worse scores on the DSST.
CONCLUSIONS: Neurologic deficits in schizophrenia have an intrinsic organization that appears to have clinical significance, highlighting the continued utility of the NES in studies of neurological deficits in schizophrenia patients. The theoretical underpinning of this organization remains unclear. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2010        PMID: 20855185     DOI: 10.1016/j.schres.2010.08.036

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

1.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

2.  Longitudinal trajectory of early functional recovery in patients with first episode psychosis.

Authors:  Mei-Hua Hall; Kristina M Holton; Dost Öngür; Debra Montrose; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2019-02-28       Impact factor: 4.939

3.  Socioeconomic disadvantage and neural development from infancy through early childhood.

Authors:  Galen Chin-Lun Hung; Jill Hahn; Bibi Alamiri; Stephen L Buka; Jill M Goldstein; Nan Laird; Charles A Nelson; Jordan W Smoller; Stephen E Gilman
Journal:  Int J Epidemiol       Date:  2015-12-16       Impact factor: 7.196

Review 4.  miR-137: a new player in schizophrenia.

Authors:  Jingwen Yin; Juda Lin; Xudong Luo; Yanyan Chen; Zheng Li; Guoda Ma; Keshen Li
Journal:  Int J Mol Sci       Date:  2014-02-21       Impact factor: 5.923

5.  Association of a miRNA-137 polymorphism with schizophrenia in a Southern Chinese Han population.

Authors:  Guoda Ma; Jingwen Yin; Jiawu Fu; Xudong Luo; Haihong Zhou; Hua Tao; Lili Cui; You Li; Zhixiong Lin; Bin Zhao; Zheng Li; Juda Lin; Keshen Li
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

6.  Exploratory factor structure of the neurological evaluation scale in black africans with first episode schizophrenia.

Authors:  Akin Ojagbemi; Robin Emsley; Oye Gureje
Journal:  Data Brief       Date:  2016-01-06

7.  Neurological soft signs: Effects of trait schizotypy, psychological distress and auditory hallucination predisposition.

Authors:  Saskia de Leede-Smith; Steven Roodenrys; Lauren Horsley; Shannen Matrini; Erin Mison; Emma Barkus
Journal:  Schizophr Res Cogn       Date:  2016-12-23

Review 8.  The neural substrates of neurological soft signs in schizophrenia: a systematic review.

Authors:  Genelle D Samson; Adrienne C Lahti; Nina V Kraguljac
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-26

9.  Potential Impact of miR-137 and Its Targets in Schizophrenia.

Authors:  Carrie Wright; Jessica A Turner; Vince D Calhoun; Nora Perrone-Bizzozero
Journal:  Front Genet       Date:  2013-04-26       Impact factor: 4.599

10.  Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables.

Authors:  Miao Yu; XiaoWei Tang; Xiang Wang; XiangRong Zhang; XiaoBin Zhang; WeiWei Sha; ShuQiao Yao; Ni Shu; XiangYang Zhang; ZhiJun Zhang
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.